Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market Growth, Trends & Forecasts (2017 - 2022)

The Global market for Isothermal Nucleic Acid Amplification Technology is poised to reach $2.1 billion by the end of 2020 growing at a CAGR of 10.5%.

The PCR is a familiar approach to amplify a specific DNA sequence. As routine as PCR is in molecular biology, there are other approached to amplify a specific DNA sequence. These alternative methods do not require changing the reaction temperature and are, therefore often referred to as sequence-specific isothermal amplification protocols and are also called as INAAT.

Isothermal amplification protocols are varied and have varied advantages. However, some common advantages are that isothermal techniques are extremely fast and they do not require thermo cyclers. Nucleic Acid Testing (NAT) promises rapid, sensitive and specific diagnosis of infectious, inherited and genetic disease.

The next generation of diagnostic devices will interrogate the genetic determinants of such conditions at the point-of-care, affording clinicians prompt reliable diagnosis from which to guide more effective treatment.Currently, North America is the largest market for INAAT. This is due to the increased awareness about the cost benefits involved in INAAT procedures. Asia Pacific is the fastest growing segment. The INAAT market can be segmented on the basis of Technology (NASBA, HAD, ICAN, LAMP, RCA, SDA, SPIA), Applications (Oncology, Laboratory Research, Molecular diagnostics, blood screening & Infectious disease diagnostics), End user ( Hospitals, Biotechnology, Reference Laboratories) and Geography (North America, Europe, APAC & RoW).DriversIncrease in the adoption of new INAAT methods over PCR, rise in the miniaturization of nucleic acid based diagnostics, increasing incidences of chronic disease, increase in the available disposable income in the developing economies, and upsurge in the molecular diagnostics market are the major factors driving the growth of the market.RestraintsLack of awareness over new diagnostic technologies, threatening opposition from PCR technologies and stringent regulatory framework are the major challenges faced by the INAAT market.

What the report offers

Market Definition for the specified topic along with identification of key drivers and restraints for the market.

Market analysis for the Global INAAT market, with region specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.

Identification and analysis of the Macro and Micro factors that affect the Global INAAT market on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

1. Introduction

1.1 Report Description

1.2 Research Methodology

2. Key Findings

3. Executive Summary



4. Market Dynamics

4.1 Market Segmentation

4.2 Market Drivers

4.2.1 Upsurge in the molecular diagnostics market

4.2.2 Rise in demand for low cost and effective diagnostics procedures

4.2.3 Increase in the disposable income from the developing economies

4.2.4 Increasing incidences of chronic diseases and aging population boosting the market growth

4.2.5 Increase in the adoption of INAAT over PCR booming the market growth

4.2.6 Rise in the miniaturization of nucleic acid based diagnostics

4.3 Market Restraints

4.3.1 Threatening opposition from PCR technologies will pose as a major challenge

4.3.2 Stringent Regulatory framework

4.3.3 Lack of awareness over new diagnostics technolgies

5. Global Market Segmentation

5.1 By Technology

5.1.1 NASBA

5.1.2 HAD

5.1.3 ICAN

5.1.4 LAMP

5.1.5 NEaR

5.1.6 RCA

5.1.7 RPA

5.1.8 SDA

5.1.9 SMAP2

5.1.10 SPIA

5.2 By Applications

5.2.1 Oncology

5.2.2 Laboratory Research

5.2.3 Molecular Diagnostics

5.2.4 Blood Screening

5.2.5 Infectious Disease Diagnostics

5.2.6 Others

5.3 By End User

5.3.1 Hospitals

5.3.2 Biotechnology

5.3.3 Reference Laboratories

5.3.4 Others

5.4 By Geography

5.4.1 North America

5.4.1.1 US

5.4.1.2 Canada

5.4.1.3 Mexico

5.4.2 Europe

5.4.2.1 UK

5.4.2.2 Germany

5.4.2.3 France

5.4.2.4 Spain

5.4.2.5 Italy

5.4.2.6 Rest of Europe

5.4.3 Asia Pacific

5.4.3.1 China

5.4.3.2 Japan

5.4.3.3 India

5.4.3.4 South Korea

5.4.3.5 Rest of Asia Pacific

5.4.4 Rest of the World



6. Competitive Landscape

6.1 Mergers & Acquisitions

6.2 Agreements, Collaborations & Partnerships

6.3 New Product Launches

6.4 Recommendations to new market players

7. Company Profiles

7.1 Alere

7.2 Becton, Dickinson & Company

7.3 Biomeriux

7.4 Hologica

7.5 Lucigen

7.6 Quidel Corporation

7.7 New England Biolabs

7.8 Nugen

7.9 Qiagen

7.10 Ustar Biotechnologies

8. Appendix

8.1 Abbreviations

8.2 Sources

8.3 Bibliography

8.4 Disclaimer

Content are not available

Choose License Type